Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06613698 · ClinicalTrials.gov registry record · Phase 2

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

A Phase 2 study of Liver Diseases, Alcoholic, sponsored by GlaxoSmithKline.

Recruiting
Registry status
Phase 2
Development phase
393
Enrollment target
20
Study locations

NCT06613698 is a Phase 2 study of Liver Diseases, Alcoholic that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 393 participants. The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06613698, a Phase 2 study of Liver Diseases, Alcoholic, is actively recruiting participants, sponsored by GlaxoSmithKline.

RECRUITING
Registry status
Phase 2
Development phase
393 participants
Enrollment target
20
Study locations

Study Summary

The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG GSK4532990

Study Locations (20)

Arizona

  • GSK Investigational Site - Chandler
  • GSK Investigational Site - Phoenix
  • GSK Investigational Site - Tucson

California

  • GSK Investigational Site - Davis
  • GSK Investigational Site - Los Angeles
  • GSK Investigational Site - Los Angeles

Florida

  • GSK Investigational Site - Brandon
  • GSK Investigational Site - Miami Lakes

Texas

  • GSK Investigational Site - Arlington
  • GSK Investigational Site - Austin

Georgia

  • GSK Investigational Site - Atlanta

Indiana

  • GSK Investigational Site - Indianapolis

Kansas

  • GSK Investigational Site - Topeka

Louisiana

  • GSK Investigational Site - Marrero

Trial Details

FieldValue
Enrollment Target 393 participants
Start Date 2024-09-27
Est. Completion 2028-03-30
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT06613698

The ClinicalTrials.gov registry entry for NCT06613698 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 393 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Liver Diseases, Alcoholic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06613698 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Arizona, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06613698 about?

NCT06613698 is a clinical study titled "A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease". The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.

What is the current status of trial NCT06613698?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 393 participants. The study started on 2024-09-27. Estimated completion is 2028-03-30.

What conditions does trial NCT06613698 study?

This clinical trial studies the following conditions: Liver Diseases, Alcoholic.

What interventions are being tested in trial NCT06613698?

The interventions under investigation include: Placebo (DRUG), GSK4532990 (DRUG).

Who is sponsoring clinical trial NCT06613698?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06613698 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Liver Diseases, Alcoholic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.